ClinicalTrials.gg
RecruitingNCT04862507I-LASTUpdated May 24, 2023

Improving Low ASPECTS Stroke Thrombectomy

An observational study in Acute Ischemic Stroke, sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Ischemic Stroke with a site in Germany — 41 open to participants now, 50 under way, 5 of them phase 3. Ischemic Stroke · Germany.

Planned enrollment
27th of 61
500 · median 410
Started
2023
with 12 others
Observational
61 of 164
20 open now
Primary completion
2027-01
later than 22 of 49 live
Registered
111th of 164
by date
Lead sponsor
7 of 164
Universitätsklinikum Hamburg-Eppendorf

Among the 164 studies in Ischemic Stroke with a site in Germany, this one is the 27th largest by planned enrollment of the 61 observational ones that give a count, is one of 13 that started in 2023, is one of 61 observational ones, reaches primary completion later than 22 of the 49 other live ones, and was the 111th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

41 of the 164 studies in Ischemic Stroke with a site in Germany are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Ischemic Stroke with a site in Germany, or all of them as a file.
02

Study summary

Improving Low ASPECTS Stroke Thromectomy (I-LAST) is an academic, independent, prospective, multicenter, observational registry study. Consecutive patients treated with endovascular stroke treatment will be enrolled in German stroke centers. Patients receive regular care and data will be collected as part of clinical routine. Baseline clinical and procedural information as well clinical follow-up information during in-hospital stay, and up to 90 days of stroke onset are collected. Data collected include demographics, National Institute of Health Stroke Scale (NIHSS) on admission, pre-treatment ASPECTS, information on timing and success of interventional treatment, procedural complications, intracranial hemorrhage, and functional outcome. Advanced imaging biomarkers will be tested and validated aiming to improve treatment selection and outcome prediction of patients presenting with extensive baseline infarction.

Read the detailed description

This study aims to investigate the role of advanced imaging biomarkers in patients with large early infarct, in particular quantitative lesion water uptake (Minnerup et al. Annals of Neurology 2016), arterial and venous collateral circulation (Faizy et al. Radiology 2021), and multivariate CTP-derived parameters (Kemmling et al. JCBFM 2015). The goal is to use these imaging biomarkers as specific selection criterion to predict clinical benefit after reperfusion despite extensive baseline infarct lesions, also as a method of monitoring adjuvant neuroprotective agents after reperfusion therapy (for instance anti-edematous medication).

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All acute stroke patients with the clinical diagnosis of acute ischemic stroke with a ASPECTS 0f 0-5 on baseline imaging; Age >18 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of acute ischemic stroke
  • ASPECTS of 0-5
  • Confirmed diagnosis of persistent occlusion of terminal carotid artery, middle cerebral artery (M1 or M2), or basilar artery consistent with symptoms
  • Age >18 years
  • Ethic approval in process

Exclusion criteria

Exclusion Criteria:

none

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
90 Days
Patient registry
Yes

Groups and cohorts

  • Stroke Patients with an ASPECTS of 0-5 on baseline neuroimaging undergoing thrombectomy

    acute stroke patients treated with endovascular treatment combined with thrombolysis or without previous thrombolysis Intervention.

    Other: Telephone call on day 90 · Diagnostic Test: Quantification of lesion water uptake by CT densitometry

  • Stroke Patients with an ASPECTS of 0-5 on baseline neuroimaging not undergoing thrombectomy

    acute stroke patients treated with or without thrombolysis

    Other: Telephone call on day 90 · Diagnostic Test: Quantification of lesion water uptake by CT densitometry

Interventions

  • OtherTelephone call on day 90

    telephone call on day 90 to assess the primary outcome (mRs 90)

  • Diagnostic testQuantification of lesion water uptake by CT densitometry

    Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging

06

What researchers measure

Primary outcomes

  1. modified ranking scale on day (mRs) day 90

    mRs: modified ranking scale; the scale is a commonly used measurement for the degree of disability or dependence in the daily activities of people who have suffered a stroke; scale range 0-6, with 0 - No symptoms. 1 - No significant disability. Able to carry out all usual activities, despite some symptoms. 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. publication: van Swieten J, Koudstaal P, Visser M, Schouten H, et al. (1988). "Interobserver agreement for the assessment of handicap in stroke patients". Stroke. 19 (5): 604-607. doi:10.1161/01.str.19.5.604.

    Time frame: 90 days

Secondary outcomes

  1. Ischemic lesion water uptake on admission

    Ischemic lesion water uptake is a CT based quantitative imaging biomarker to assess ischemic edema based on densitometry

    Time frame: 0-24 hours after symptom onset

  2. Ischemic lesion water uptake on follow-up imaging

    Ischemic lesion water uptake is a CT based quantitative imaging biomarker to assess ischemic edema based on densitometry

    Time frame: 24-48 hours after admission

07

Study locations

8 of 8 sites recruiting
  • Charite University Berlin
    Berlin, Germany
    Enrolling by invitation
  • Hospital Bremen-Mitte
    Bremen, Germany
    Enrolling by invitation
  • University Medical Center Hamburg-Eppendorf
    Hamburg, 20251, Germany
    Recruiting
    • Gabriel Broocks, MD · Contact
  • Westpfalzklinikum
    Kaiserslautern, Germany
    Enrolling by invitation
  • University Hospital Marburg
    Marburg, Germany
    Recruiting
    • Andre Kemmling, MD · Contact
  • University Münster
    Münster, Germany
    Enrolling by invitation
  • University Rostock
    Rostock, Germany
    Enrolling by invitation
  • University Basel
    Basel, Switzerland
    Enrolling by invitation
08

References and documents

Individual participant data

Plan to share: Undecided — Data will be shared upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jan 2027, 44 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 44 months is below that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2021
First posted
Apr 28, 2021
StartActual
May 1, 2023
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2028
Last update
May 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04862507
Collaborators
University of Kaiserslautern, University Hospital Muenster, University of Rostock, University Hospital, Basel, Switzerland, Charite University, Berlin, Germany, Klinikum Bremen-Mitte, gGmbH
Responsible party
Gabriel Broocks (Assistant Professor, Principal Investigator, Universitätsklinikum Hamburg-Eppendorf) — Principal investigator
First posted
Apr 28, 2021
Start date
May 1, 2023
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
May 24, 2023

Study contacts

Gabriel Broocks, MD
Contact
g.broocks@uke.de
+4915222817182
Andre Kemmling, MD, MHBA
Contact
akemmling@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion